Emulate and AstraZeneca announce Organs-on-Chips partnership
AstraZeneca has announced a collaboration with Emulate to develop and embed the start-up’s...
Trending:
-
![]()
LIDDS verifies NanoZolid for controlled release of cancer drugs
-
![]()
Merck’s Keytruda combo could be a winner for NSCLC and other solid tumours
-
![]()
ECCMID 2018: Ribaxamase demonstrates protection of the microbiome following Ceftriaxone treatment
-
![]()
Algorithm optimises peptides to target drug-resistant bacteria
-
![]()
Computer simulation offers digital penicillin production
-
![]()
Synthetic circuits and feedback loops enable bacteria to produce drugs
Most Read
Company A-Z
Latest Content
Zepatier for the Treatment of Chronic Hepatitis C GT1 and GT4 Infection
Zepatier is a once-daily, oral selective combination of nonstructural 5A (NS5A) replication complex inhibitor elbasvir (50mg) and non-structural 3/4A protease inhibitor grazoprevir (100mg).
May’s top news stories
Abivax unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory diseases; and Cancer Research UK and Experimental Cancer Medicine Centres (ECMC) Network joint venture (JV) Combinations Alliance started the SeluDex trial, a Phase I clinical study to evaluate selumetinib in combination with dexamethasone for treating leukaemia.
Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)
Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.
Malvern Panalytical Introduces New Zetasizer Pro And Zetasizer Ultra
Malvern Panalytical has announced two new additions to its Zetasizer range, the Zetasizer® Pro and Ultra systems.
Emulate and AstraZeneca announce Organs-on-Chips partnership
AstraZeneca has announced a collaboration with Emulate to develop and embed the start-up’s Organs-on-Chips technology within its Innovative Medicines and Early Development (IMED) Drug Safety organisation laboratories.
LIDDS verifies NanoZolid for controlled release of cancer drugs
Local Intelligent Drug Delivery System (LIDDS) has verified its NanoZolid technology as a subcutaneous depot for systemic delivery of pharmaceutically active drugs, intended to revolutionise the administration of cancer treatments.
Dynamic Light Scattering – Common Terms Defined
There are a number of sources of information that give a mathematical description of the terms used in light scattering. However, these will not usually give assistance in understanding their practical application.
Merck’s Keytruda combo could be a winner for NSCLC and other solid tumours
The FDA has granted priority review for Merck’s Keytruda (pembrolizumab) + Alimta (pemetrexed injection) + platinum-based chemotherapy combination as a first-line treatment for patients with metastatic non-squamous, non-small cell lung cancer (NSCLC).
April’s top news stories
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended three medications for approval during its April meeting, and Drug development company Proniras has entered a contract with the US Biomedical Advanced Research and Development Authority (BARDA) to explore Eli Lilly’s investigational migraine drug tezampanel as a potential treatment for nerve agent-induced seizures.
FlexyPAT as a Calorimeter
FlexyPAT is a modular process automation technology that enables automated, customer-specific lab reactor systems to be implemented cost-effectively. With FlexyPAT, you have a strong and flexible tool.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
